37,998 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 37,998 shares of the biopharmaceutical company’s stock, valued at approximately $11,439,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. iA Global Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares during the last quarter. SCS Capital Management LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $34,784,000. Hussman Strategic Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $2,505,000. Hsbc Holdings PLC grew its stake in Alnylam Pharmaceuticals by 22.6% in the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $50,773,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ALNY shares. Chardan Capital restated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, August 19th. They issued an “outperform” rating and a $318.00 price target on the stock. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Needham & Company LLC decreased their price objective on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price for the company in a report on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $237.10 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The firm has a market cap of $31.73 billion, a price-to-earnings ratio of 44.07 and a beta of 0.30. The business’s fifty day moving average is $262.62 and its 200-day moving average is $293.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.51) earnings per share. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.